KRAS mutations mediate the noncanonical reprogramming, which can elevate the levels of glucose and glycolytic intermediates, cellular redox potential, fatty acids, and glutamine uptake that provide nearly perfect conditions for cancer cells to thrive (Figure 2) [45,46]. This evidence concerns the gene KRAS and cancer.